The conversation discusses a new study on topical pumpkin seed oil for hair loss in mice. Treatments mentioned include Minoxidil, finasteride, and RU58841.
Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.
The conversation discusses the use of peptides C60 and GHK-Cu for hair growth. Participants are sharing their experiences or knowledge about these treatments.
The user experienced negative side effects from oral minoxidil, including cardiac issues and excessive sweating, and decided to switch to topical minoxidil while using other treatments like RU58841, Setipiprant, Azelaic acid, and latanoprost. Another user suggested splitting the oral minoxidil dose to reduce side effects.
The conversation is about someone considering adding topical Cetirizine 1% to their existing hair loss treatment regimen and seeking advice on where to buy it and others' experiences with it.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.